Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Form 4 overview: Executive Chairman and Director Matthew Rabinowitz of Natera, Inc. (NTRA) reported a series of six open-market sales executed by his spouse between 15 May 2025 and 13 Jun 2025.
- Total shares sold: 54,000
- Sale prices: $150.20 – $165.85
- Approximate gross proceeds: ≈ $8.4 million
- Indirect share balance (spouse): reduced from 74,000 to 30,000
- Direct ownership (Rabinowitz): 2,362,570 shares unchanged
No derivative transactions were reported, and the filing does not indicate a Rule 10b5-1 trading plan. The sales represent a 73% reduction of the spouse’s holdings but leave the insider with a substantial direct stake, suggesting continued alignment with shareholders despite the liquidity event.
Form 4 Overview – Natera, Inc. (NTRA)
The filing discloses that co-founder and director Jonathan Sheena sold Natera common stock on two separate dates under previously adopted Rule 10b5-1 trading plans.
- 18 Jun 2025: Direct sale of 3,070 shares at a weighted-average price of $167.2869 per share. Direct ownership after the sale is 248,774 shares.
- 16 Jun 2025: Eight block sales by Caraluna 1 Trust and Caraluna 2 Trust (both held for the benefit of trust beneficiaries and disclaimed for beneficial-ownership purposes). The trusts sold an aggregate of 3,000 shares at weighted-average prices ranging from $162.04 – $165.55 per share. Post-transaction holdings were 38,379–37,282 shares per trust line item.
No derivative security transactions were reported. All sales were executed automatically under the trading plans adopted on 11 Dec 2024 (direct holdings) and 7 Jun 2024 (trust holdings), limiting discretionary timing by the insider.
In total, the reporting person disposed of 6,070 shares, representing a low-single-digit percentage of his reported direct and indirect ownership. While insider selling can be perceived negatively, the modest size relative to the remaining stake and the use of pre-arranged 10b5-1 plans mitigate signal risk.
Form 144 Notice of Proposed Sale filed by Natera insider indicates planned sale of 19,908 shares of common stock with an aggregate market value of $3,335,585.40. The sale is scheduled for June 18, 2025, to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
The securities were originally acquired as Restricted Stock Units from the issuer on September 21, 2020. The seller, Daniel Rabinowitz, has conducted three previous sales in the past 3 months totaling 3,867 shares with gross proceeds of $566,033.98:
- April 28, 2025: 1,993 shares for $303,299.52
- April 21, 2025: 470 shares for $68,407.52
- March 31, 2025: 1,404 shares for $194,326.94
The company currently has 136,546,580 shares outstanding. This proposed sale represents approximately 0.015% of total shares outstanding.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What core services does Natera Inc offer?
How does Natera ensure accuracy in its testing processes?
What is non-invasive prenatal testing (NIPT) and how does Natera apply it?
What role does bioinformatics play in Natera's diagnostic solutions?
How does Natera address the needs of oncology patients?
In what ways does Natera contribute to the field of genetic diagnostics?
How is Natera positioned within the competitive landscape of diagnostic companies?
